Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
Author(s):
Victoria G. Hall, Thi H.O. Nguyen, Lilith F. Allen, Louise C. Rowntree, Lukasz Kedzierski, Brendon Y. Chua, Chhay Lim, Natalie R. Saunders, Emily Klimevski, Gayani S. Tennakoon, John F. Seymour, Vikas Wadhwa, Natalie Cain, Kim L. Vo, Suellen Nicholson, Theo Karapanagiotidis, Deborah A. Williamson, Karin A. Thursky, Timothy Spelman, Michelle K. Yong, Monica A. Slavin, Katherine Kedzierska, Benjamin W. Teh
Details:
Open Forum Infectious Diseases, Volume 10, Issue 11, 2023-11-01, Article number ofad550
Article Link: Click here
Affiliations:
- Peter Maccallum Cancer Centre
- Royal Melbourne Hospital
- The Peter Doherty Institute for Infection and Immunity
- University of Melbourne
- Hokkaido University
- Burnet Institute